[
    [
        {
            "time": "",
            "original_text": "晶云药物科创板IPO暂缓审议：毛利率波动较大 创新产品遭诺华起诉 诉讼纠纷",
            "features": {
                "keywords": [
                    "晶云药物",
                    "科创板",
                    "IPO",
                    "暂缓审议",
                    "毛利率波动",
                    "创新产品",
                    "诺华",
                    "起诉",
                    "诉讼纠纷"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "晶云药物科创板IPO暂缓审议：毛利率波动较大 创新产品遭诺华起诉 诉讼纠纷",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]